Kane Biotech Inc. (KNBIF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 109.47 Thousand CAD | -92.25% |
| 2022 | 1.41 Million CAD | 148.61% |
| 2021 | 568.44 Thousand CAD | 7.89% |
| 2020 | 526.85 Thousand CAD | -13.62% |
| 2019 | 609.91 Thousand CAD | 428.19% |
| 2018 | 115.47 Thousand CAD | -87.35% |
| 2017 | 912.89 Thousand CAD | 657.4% |
| 2016 | 120.53 Thousand CAD | 102.25% |
| 2015 | 59.59 Thousand CAD | 166.88% |
| 2014 | 22.33 Thousand CAD | -86.04% |
| 2013 | 159.94 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | -100.0% |
| 2007 | 17.15 Thousand CAD | -28.81% |
| 2006 | 24.09 Thousand CAD | 8.97% |
| 2005 | 22.11 Thousand CAD | 64.87% |
| 2004 | 13.41 Thousand CAD | -82.5% |
| 2003 | 76.64 Thousand CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -14.06 Thousand CAD | 99.28% |
| 2024 Q2 | 360.49 Thousand CAD | 2663.62% |
| 2023 FY | -129.12 Thousand CAD | -109.14% |
| 2023 Q3 | 315.26 Thousand CAD | -4.61% |
| 2023 Q1 | 345.04 Thousand CAD | 7.61% |
| 2023 Q2 | 330.5 Thousand CAD | -4.21% |
| 2023 Q4 | -1.95 Million CAD | -721.21% |
| 2022 Q2 | 639.21 Thousand CAD | 248.12% |
| 2022 Q4 | 320.65 Thousand CAD | 18.87% |
| 2022 FY | 1.41 Million CAD | 148.61% |
| 2022 Q1 | 183.62 Thousand CAD | -1.97% |
| 2022 Q3 | 269.74 Thousand CAD | -57.8% |
| 2021 Q2 | 83.58 Thousand CAD | -49.61% |
| 2021 Q1 | 165.87 Thousand CAD | 61.49% |
| 2021 FY | 568.44 Thousand CAD | 7.89% |
| 2021 Q3 | 131.66 Thousand CAD | 57.52% |
| 2021 Q4 | 187.31 Thousand CAD | 42.27% |
| 2020 Q2 | 115.57 Thousand CAD | -35.59% |
| 2020 Q1 | 179.41 Thousand CAD | -10.4% |
| 2020 Q4 | 102.71 Thousand CAD | -20.47% |
| 2020 FY | 526.85 Thousand CAD | -13.62% |
| 2020 Q3 | 129.15 Thousand CAD | 11.76% |
| 2019 Q2 | 82.5 Thousand CAD | -60.87% |
| 2019 Q4 | 200.23 Thousand CAD | 72.14% |
| 2019 FY | 609.91 Thousand CAD | 428.19% |
| 2019 Q3 | 116.32 Thousand CAD | 40.98% |
| 2019 Q1 | 210.84 Thousand CAD | 330.03% |
| 2018 Q4 | -91.66 Thousand CAD | -212.26% |
| 2018 Q2 | 71.65 Thousand CAD | 33.13% |
| 2018 FY | 115.47 Thousand CAD | -87.35% |
| 2018 Q3 | 81.64 Thousand CAD | 13.95% |
| 2018 Q1 | 53.82 Thousand CAD | -92.57% |
| 2017 Q4 | 724.68 Thousand CAD | 1637.65% |
| 2017 Q3 | 41.7 Thousand CAD | -39.75% |
| 2017 Q2 | 69.21 Thousand CAD | -10.44% |
| 2017 FY | 912.89 Thousand CAD | 657.4% |
| 2017 Q1 | 77.29 Thousand CAD | 140.01% |
| 2016 Q4 | 32.2 Thousand CAD | 15.17% |
| 2016 Q1 | 17.32 Thousand CAD | 75.32% |
| 2016 FY | 120.53 Thousand CAD | 102.25% |
| 2016 Q3 | 27.96 Thousand CAD | -35.03% |
| 2016 Q2 | 43.03 Thousand CAD | 148.36% |
| 2015 Q3 | 4185.00 CAD | -81.81% |
| 2015 Q4 | 9884.00 CAD | 136.18% |
| 2015 FY | 59.59 Thousand CAD | 166.88% |
| 2015 Q2 | 23 Thousand CAD | 2.15% |
| 2015 Q1 | 22.52 Thousand CAD | 105.16% |
| 2014 Q1 | - CAD | -100.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q3 | 11.35 Thousand CAD | 0.0% |
| 2014 FY | 22.33 Thousand CAD | -86.04% |
| 2014 Q4 | 10.97 Thousand CAD | -3.31% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 FY | 159.94 Thousand CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q4 | 159.94 Thousand CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q1 | - CAD | 100.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2008 FY | - CAD | -100.0% |
| 2008 Q4 | -22.4 Thousand CAD | -430.5% |
| 2008 Q2 | 10.71 Thousand CAD | 0.0% |
| 2008 Q1 | - CAD | -100.0% |
| 2008 Q3 | 6780.00 CAD | -36.69% |
| 2007 Q2 | 3514.00 CAD | -39.15% |
| 2007 Q4 | 4230.00 CAD | 16.3% |
| 2007 Q3 | 3637.00 CAD | 3.5% |
| 2007 FY | 17.15 Thousand CAD | -28.81% |
| 2007 Q1 | 5775.00 CAD | -30.7% |
| 2006 Q1 | 2921.00 CAD | 0.0% |
| 2006 FY | 24.09 Thousand CAD | 8.97% |
| 2006 Q3 | 10.49 Thousand CAD | 347.49% |
| 2006 Q2 | 2346.00 CAD | -19.69% |
| 2006 Q4 | 8333.00 CAD | -20.62% |
| 2005 Q2 | - CAD | -100.0% |
| 2005 Q4 | - CAD | 0.0% |
| 2005 FY | 22.11 Thousand CAD | 64.87% |
| 2005 Q1 | 8873.00 CAD | 137.76% |
| 2005 Q3 | - CAD | 0.0% |
| 2004 Q1 | 8902.00 CAD | -16.79% |
| 2004 FY | 13.41 Thousand CAD | -82.5% |
| 2004 Q3 | 12.18 Thousand CAD | 129.29% |
| 2004 Q2 | 5316.00 CAD | -40.28% |
| 2004 Q4 | -23.5 Thousand CAD | -292.8% |
| 2003 Q4 | 10.69 Thousand CAD | -25.63% |
| 2003 FY | 76.64 Thousand CAD | 0.0% |
| 2003 Q2 | 4694.00 CAD | 0.0% |
| 2003 Q3 | 14.38 Thousand CAD | 206.43% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 1421.304% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.27% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 98.882% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -66.55% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.065% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.908% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 420.556% |
| Marizyme, Inc. | 457.7 Thousand USD | 76.083% |
| Genus plc | 178.7 Million USD | 99.939% |
| Pharming Group N.V. | 220.1 Million USD | 99.95% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -75.923% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 73.311% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1095.182% |
| ContraFect Corporation | -154 Thousand USD | 171.084% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -42.611% |
| IMV Inc. | -962.29 Thousand USD | 111.376% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 128.25% |
| ONE Bio Corp. | 20.12 Million USD | 99.456% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.728% |
| Mesoblast Limited | -35.16 Million USD | 100.311% |
| MultiCell Technologies, Inc. | 49.32 USD | -221858.637% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.613% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.973% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -3429.014% |
| Biomind Labs Inc. | -15.42 Thousand USD | 809.738% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 109.589% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -56.386% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 188.104% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 2310.622% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 318.94% |
| Arch Therapeutics, Inc. | -2439.00 USD | 4588.315% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 22.085% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -123.865% |
| Q BioMed Inc. | -8988.00 USD | 1317.957% |
| GB Sciences, Inc. | -624.00 USD | 17643.269% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 227.249% |
| CSL Limited | 7.56 Billion USD | 99.999% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.753% |
| Enzolytics Inc. | 30.7 Thousand USD | -256.487% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 77.309% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 212.26% |
| argenx SE | 1.1 Billion USD | 99.99% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.424% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 52729.808% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 121.277% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 1336.111% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 82.269% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 230.556% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 88.92% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 98.861% |
| Kadimastem Ltd | -630.13 Thousand USD | 117.372% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.29% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1024.968% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 326.839% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 37.998% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 37.998% |
| Affymax, Inc. | 1.35 Million USD | 91.934% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 97.624% |
| CytoDyn Inc. | -29 Thousand USD | 477.483% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 75.676% |
| SYBLEU INC | 11.69 Thousand USD | -835.961% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 134.262% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 129.349% |
| Neutra Corp. | 14.33 Thousand USD | -663.655% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 233.5% |
| PureTech Health plc | -1.6 Million USD | 106.829% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 110.933% |
| IXICO plc | 3.27 Million USD | 96.652% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 115.774% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 106.112% |
| CSL Limited | 7.7 Billion USD | 99.999% |
| Cellectis S.A. | 18 Thousand USD | -508.167% |